Search This Blog

Thursday, August 21, 2014

Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies (NYSE:LLY)

Eli Lilly and Company's (NYSE: LLY) investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.



Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies (NYSE:LLY)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)